 |
|
|
|
|
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Rohn T. on PAPER: Li Z. et al., 2010, The recent study by Li et al. is an intriguing one that provides a mechanism for long-term... 4 Jun 2010.
|
|
|
 |
|
|
Rohn T. on NEWS: Who’s on First? Multiphoton Imaging Suggests Caspases, Not Tangles, This is a provocative study. It clearly supports the idea that caspase activation lies upstream... 26 May 2010.
|
|
|
|
|
|
Rohn T. on PAPER: Wang YP. et al., 2007, This eloquent study examines the post-translational modification of tau. The authors used a... 1 Jun 2007.
|
|
|
|
|
|
Rohn T. on NEWS: Tackling Alzheimer’s from the Outside in, The paper by Oddo et al, published in Neuron 2004, reaffirmed my belief that Frank LaFerla and... 13 Aug 2004.
|
|
|
|
|
|
Rohn T. on LIVE DISCUSSION: Cell Death: Time to Push It Out of the Doldrums, Yong Shen asks whether I consider caspase-mediated cleavage of MAP
or tau a normal... 25 Jun 2004.
|
|
|
|
|
|
Rohn T. on LIVE DISCUSSION: Cell Death: Time to Push It Out of the Doldrums, Yong Shen does an excellent job of summarizing some of the
important data supporting an... 23 Jun 2004.
|
|
|
|
|
|
Rohn T. on PAPER: Yang X. et al., 2004, In this study, the authors investigate the role of notch signaling during mammalian neural... 1 Jun 2004.
|
|
|
|
|
|
Rohn T. on NEWS: α-Secretase Returns to Center Stage, In this study, the authors provide the first in-
vivo demonstration of an effect on plaque... 26 May 2004.
|
|
|
|
|
|
Rohn T. on PAPER: Feng R. et al., 2004, This is an excellant paper showing the effects of knocking out PS-1 and PS-2. The major... 26 May 2004.
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our upcoming Webinar: 
